Cell type-associated traits map for the [FetalStomach_Fetal neuron][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [FetalStomach_Fetal neuron]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
2 Hour Glucose | 2-Hour Glucose | ETC | Saxena | 2010 | NA | 15234 | 1.00e-3 | 2.87e-2 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-3 | 3.32e-3 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-4 | 1.43e-2 |
BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 1.00e-3 | 3.87e-2 |
Breast Cancer | Breast Cancer | MTC | Hunter | 2007 | NA | 1145 | 5.00e-2 | 2.39e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 8.07e-3 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-2 | 7.67e-3 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-3 | 2.10e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 2.10e-2 |
Fasting Proinsulin | Fasting Proinsulin | MTC | Strawbridge | 2011 | NA | 16378 | 1.00e-3 | 1.67e-2 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 5.00e-2 | 6.11e-3 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 1.00e-2 | 4.32e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 1.98e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-2 | 1.82e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-3 | 3.22e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 4.90e-2 |
Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 1.00e-2 | 4.00e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 7.05e-5 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-2 | 4.44e-3 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 1.61e-3 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-2 | 1.52e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-3 | 3.44e-2 |
Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-2 | 3.17e-2 |
Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 2.85e-3 |
Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 1.00e-2 | 2.72e-3 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 5.00e-2 | 1.15e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 3.17e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 1.23e-2 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-2 | 8.09e-3 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-3 | 7.12e-3 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.12e-3 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.65e-2 |
Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.42e-2 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 1.00e-3 | 3.72e-2 |
BMI | BMI European | ETC | Locke | 2015 | NA | 234069 | 1.00e-5 | 1.03e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.37e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.01e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.04e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 4.49e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.47e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 2.12e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.47e-2 |
Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 5.00e-2 | 8.94e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 5.00e-2 | 4.30e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease | ETC | Pattaro | 2016 | 12385 | 104780 | 1.00e-3 | 3.36e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-3 | 3.86e-3 |
Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-3 | 2.97e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 16434 | 5.00e-2 | 3.38e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 5.00e-2 | 3.34e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-2 | 3.43e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.97e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.32e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 8.26e-3 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-3 | 6.37e-3 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 4.75e-2 |
Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 5.00e-2 | 3.46e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 1.16e-2 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 8.46e-3 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 3.40e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 4.64e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 2.25e-2 |
Smoking | Current Vs Former Discrete | MTC | Furberg | 2010 | 20619 | 15226 | 5.00e-2 | 4.80e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 1.93e-2 |
Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 4.79e-2 |
Tanner Stage | Tanner Stage Females | MTC | Cousminer | 2014 | NA | 6144 | 5.00e-2 | 4.50e-2 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 4.16e-2 |
Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.90e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 3.22e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 4.75e-3 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-2 | 3.09e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 2.28e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 3.09e-2 |
Glycine level | Glycine levels, both male and female | ETC | Jia | 2019 | NA | 30118 | 5.00e-2 | 4.10e-2 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-3 | 6.76e-3 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 7.43e-4 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-5 | 4.79e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-3 | 4.31e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-4 | 4.02e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.42e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 6.19e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 2.41e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-4 | 4.00e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.80e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.06e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-4 | 2.34e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-5 | 1.65e-3 |
Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 4.85e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 5.00e-2 | 3.99e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 6.55e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-4 | 3.56e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 5.00e-2 | 3.23e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 8.83e-3 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 5.00e-2 | 1.37e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-2 | 1.36e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-2 | 5.29e-3 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-4 | 2.35e-2 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 3.62e-3 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-3 | 2.39e-2 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-4 | 3.51e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 4.01e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 5.00e-2 | 1.90e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-2 | 4.23e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 3.91e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 2.07e-2 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-2 | 2.40e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 2.41e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 3.47e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-2 | 2.52e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-3 | 2.57e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.19e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.91e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.59e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.39e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.89e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 4.88e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 1.91e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 5.00e-2 | 1.95e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-5 | 2.40e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 5.00e-2 | 3.17e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 1.15e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 5.70e-3 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 1.96e-3 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 1.16e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.90e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 4.18e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 5.00e-2 | 6.67e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-2 | 2.25e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 1.97e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-4 | 3.45e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 5.00e-2 | 1.51e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-2 | 2.30e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-3 | 2.86e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-4 | 1.58e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-5 | 1.87e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 3.44e-2 |
Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 1.00e-2 | 3.11e-2 |
Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 1.00e-3 | 2.29e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 1.81e-3 |
BMI at birth | BMI at birth | ETC | Helgeland O | 2019 | NA | 9,286 | 5.00e-2 | 1.87e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 1.00e-3 | 2.49e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.15e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.28e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.29e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.15e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.80e-3 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.26e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.52e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.88e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.62e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 8.04e-3 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.86e-3 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.57e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.69e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.14e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.27e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.19e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.42e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.04e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.54e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.50e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.52e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.10e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.27e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.34e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.91e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.34e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.16e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.13e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.42e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 1.83e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-2 | 2.52e-2 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 2.53e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-2 | 3.77e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-3 | 8.46e-3 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 1.00e-3 | 2.29e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 1.32e-2 |
COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 1.00e-2 | 2.43e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.